AIM
ANIP icon

Acrospire Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Acrospire Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-48
Closed -$2K – 77
2017
Q2 		$2K Buy
+48
New +$2.32K ﹤0.01% 2056
2016
Q4 		– Sell
-2,621
Closed -$174K – 2179
2016
Q3 		$174K Hold
2,621
– – 0.12% 213
2016
Q2 		$146K Sell
2,621
-200
-7% -$9.72K 0.11% 206
2016
Q1 		$95K Buy
+2,821
New +$95.7K 0.07% 350

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Acrospire Investment Management's ANIP Position: Q3 2017 in Review

Acrospire Investment Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 48 shares — an estimated $2K sold.

Acrospire Investment Management first reported a position in ANIP in Q1 2016 and held it in 4 quarters. The position peaked at $174K in Q3 2016. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

  • Acrospire Investment Management reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 48 ANI Pharmaceuticals shares in Q3 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in ANI Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's ANI Pharmaceuticals position peaked at $174K in Q3 2016.
  • 146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.